Semantic Scholar Open Access 2016 549 sitasi

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Xiuyan Wang I. Rivière

Abstrak

The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this technology. Product quality needs to be built-in within every step of the manufacturing process. We summarize herein the requirements and logistics to be considered, as well as the state of the art manufacturing platforms available. CAR-T cell therapy may be on the verge of becoming standard of care for a few clinical indications. Yet, many challenges pertaining to manufacturing standardization and product characterization remain to be overcome in order to achieve broad usage and eventual commercialization of this therapeutic modality.

Topik & Kata Kunci

Penulis (2)

X

Xiuyan Wang

I

I. Rivière

Format Sitasi

Wang, X., Rivière, I. (2016). Clinical manufacturing of CAR T cells: foundation of a promising therapy. https://doi.org/10.1038/mto.2016.15

Akses Cepat

Lihat di Sumber doi.org/10.1038/mto.2016.15
Informasi Jurnal
Tahun Terbit
2016
Bahasa
en
Total Sitasi
549×
Sumber Database
Semantic Scholar
DOI
10.1038/mto.2016.15
Akses
Open Access ✓